Biotech

All Articles

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of notable leadership hirings, shootings and re...

Lykos will certainly talk to FDA to reconsider its own decision complying with denial of MDMA therapy for trauma

.Complying with an unsatisfactory presenting for Lykos Therapies' MDMA applicant for post-traumatic ...

AN 2 one-halfs census, quits period 3 test after data disappoint

.AN2 Therapies is actually reassessing its service in response to poor midphase records, pledging to...

Merck spends $700M for bispecific, spying autoimmune position as well as opportunity to test Amgen in cancer cells

.Merck &amp Co. is actually paying $700 million ahead of time to challenge Amgen in a blood cancer m...

Gilead pays out J&ampJ $320M to go out licensing package for seladelpar

.With Gilead Sciences on the verge of an FDA selection for its own liver ailment drug seladelpar, th...

' All palms on deck' at Lilly as peers target being overweight market

.Chief executive officer David Ricks can easily see the providers establishing tents at basecamp res...

Entero laying off workers, leaving office and also stopping briefly R&ampD

.Cushion Liquidators has actually turned Entero Therapeutics white colored as a piece. The collector...

Exelixis falls ADC after determining it is actually no match for Tivdak

.Exelixis is quiting on its own tissue element (TF)- targeting antibody-drug conjugate after ending ...

Relay dislikes SHP2 inhibitor after Genentech leaves behind

.3 weeks after Roche's Genentech system left an SHP2 inhibitor treaty, Relay Rehab has affirmed that...

Stoke's Dravet disorder med released of predisposed clinical grip

.Stoke Therapeutics' Dravet syndrome drug has actually been actually devoid of a partial grip, clear...